Unknown

Dataset Information

0

Repurposing a human acetyl-CoA carboxylase inhibitor firsocostat to treat fungal candidiasis alone and in combination.


ABSTRACT: Opportunistic fungal infections, particularly caused by Candida albicans, remain a common cause of high morbidity and mortality in immunocompromised patients. The escalating prevalence of antifungal drug resistance necessitates the immediate exploration of alternative treatment strategies to combat these life-threatening fungal diseases. In this study, we investigated the antifungal efficacy of firsocostat, a human acetyl-CoA carboxylase (ACC) inhibitor, against C. albicans. Firsocostat alone displayed moderate antifungal activity, while combining it with voriconazole, itraconazole, or amphotericin B exhibited synergistic effects across almost all drug-sensitive and drug-resistant C. albicans strains tested. These observed synergies were further validated in two mouse models of oropharyngeal and systemic candidiasis, where the combination therapies demonstrated superior fungicidal effects compared to monotherapy. Moreover, firsocostat was shown to directly bind to C. albicans ACC and inhibit its enzymatic activity. Sequencing spontaneous firsocostat-resistant mutants revealed mutations mapping to C. albicans ACC, confirming that firsocostat has retained its target in C. albicans. Overall, our findings suggest that repurposing firsocostat, either alone or in combination with other antifungal agents, holds promising potential in the development of antifungal drugs and the treatment of candidiasis.

SUBMITTER: Chen T 

PROVIDER: S-EPMC10777831 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Repurposing a human acetyl-CoA carboxylase inhibitor firsocostat to treat fungal candidiasis alone and in combination.

Chen Tianyu T   Yao Jing J   Quan Keao K   Xu Jingchen J   Hang Xudong X   Tong Qian Q   Liu Genyan G   Luo Peipei P   Zeng Liping L   Feng Ganzhu G   Bi Hongkai H  

Antimicrobial agents and chemotherapy 20231129 1


Opportunistic fungal infections, particularly caused by <i>Candida albicans</i>, remain a common cause of high morbidity and mortality in immunocompromised patients. The escalating prevalence of antifungal drug resistance necessitates the immediate exploration of alternative treatment strategies to combat these life-threatening fungal diseases. In this study, we investigated the antifungal efficacy of firsocostat, a human acetyl-CoA carboxylase (ACC) inhibitor, against <i>C. albicans</i>. Firsoc  ...[more]

Similar Datasets

| S-EPMC4833862 | biostudies-literature
| S-EPMC2529255 | biostudies-literature
| S-EPMC7468331 | biostudies-literature
| S-EPMC8658010 | biostudies-literature
| S-EPMC3031740 | biostudies-literature
| S-EPMC2889071 | biostudies-literature
| S-EPMC3264756 | biostudies-literature
| S-EPMC10594767 | biostudies-literature
| S-EPMC7259786 | biostudies-literature
| S-EPMC10017426 | biostudies-literature